R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

• Diana Al-Sarayfi,
• Frederik O. Meeuwes,
• Müjde Durmaz,
• Djamila E. Issa,
• Rolf E. Brouwer,
• Aart Beeker,
• Anna van Rhenen,
• Pim G. N. J. Mutsaers,
• Lara H. Böhmer,
• Marjolein W. M. van der Poel,
• Liane te Boome,
• Tom van Meerten,
• Martine E. D. Chamuleau,
• Josée M. Zijlstra,
• Mirian Brink,
• Marcel Nijland

Affiliations

Diana Al-Sarayfi

Department of Hematology, University Medical Center Groningen

Frederik O. Meeuwes

Department of Hematology, Treant Hospital

Müjde Durmaz

Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL)

Djamila E. Issa

Department of Internal Medicine, Jeroen Bosch Hospital

Rolf E. Brouwer

Department of Internal Medicine, Reinier de Graaf Gasthuis

Aart Beeker

Department of Oncology, Spaarne Gasthuis

Anna van Rhenen

Department of Hematology, Cancer Center, UMC Utrecht

Pim G. N. J. Mutsaers

Department of Hematology, Erasmus MC Cancer Institute

Lara H. Böhmer

Department of Hematology, Haga Teaching Hospital

Marjolein W. M. van der Poel

Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center

Liane te Boome

Department of Hematology, Haaglanden Medical Center

Tom van Meerten

Department of Hematology, University Medical Center Groningen

Martine E. D. Chamuleau

Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam

Josée M. Zijlstra

Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam

Mirian Brink

Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL)

Marcel Nijland

Department of Hematology, University Medical Center Groningen